Arrowhead Pharmaceuticals (ARWR) Competitors $16.76 -2.09 (-11.09%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$16.86 +0.10 (+0.60%) As of 07/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. BBIO, VRNA, BPMC, ROIV, ELAN, RGC, LEGN, RVMD, GRFS, and TGTXShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Legend Biotech (LEGN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Elanco Animal Health Regencell Bioscience Legend Biotech Revolution Medicines Grifols TG Therapeutics BridgeBio Pharma (NASDAQ:BBIO) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do analysts prefer BBIO or ARWR? BridgeBio Pharma presently has a consensus price target of $61.20, suggesting a potential upside of 31.58%. Arrowhead Pharmaceuticals has a consensus price target of $43.71, suggesting a potential upside of 160.83%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility & risk, BBIO or ARWR? BridgeBio Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Is BBIO or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-524.25% N/A -94.43% Arrowhead Pharmaceuticals N/A -45.33%-12.49% Which has higher valuation and earnings, BBIO or ARWR? BridgeBio Pharma has higher revenue and earnings than Arrowhead Pharmaceuticals. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M39.80-$535.76M-$3.53-13.18Arrowhead Pharmaceuticals$3.55M651.99-$599.49M-$1.40-11.97 Do insiders and institutionals hold more shares of BBIO or ARWR? 99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to BBIO or ARWR? In the previous week, BridgeBio Pharma had 22 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 25 mentions for BridgeBio Pharma and 3 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.39 beat BridgeBio Pharma's score of 0.41 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBridgeBio Pharma beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.60B$2.95B$5.54B$9.40BDividend YieldN/A2.44%3.75%4.03%P/E Ratio-11.9719.7528.0119.79Price / Sales651.99298.31432.5697.34Price / CashN/A42.5936.1658.27Price / Book10.887.678.125.65Net Income-$599.49M-$55.28M$3.25B$257.91M7 Day Performance-8.47%4.85%1.64%3.35%1 Month Performance7.30%11.70%7.27%11.09%1 Year Performance-40.78%3.69%32.88%18.99% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals3.8448 of 5 stars$16.76-11.1%$43.71+160.8%-39.4%$2.60B$3.55M-11.97400News CoveragePositive NewsAnalyst DowngradeBBIOBridgeBio Pharma4.6157 of 5 stars$47.69+2.6%$61.20+28.3%+79.4%$9.06B$221.90M-13.51400Analyst RevisionVRNAVerona Pharma PLC American Depositary Share2.3966 of 5 stars$104.67-0.2%$109.00+4.1%+364.6%$8.91B$42.28M-52.3430High Trading VolumeBPMCBlueprint Medicines1.0619 of 5 stars$129.36+0.0%$128.25-0.9%+14.1%$8.35B$508.82M-52.37640News CoverageAnalyst UpgradeHigh Trading VolumeROIVRoivant Sciences2.7193 of 5 stars$11.63+2.4%$16.50+41.9%+3.0%$7.91B$29.05M-46.52860ELANElanco Animal Health2.0442 of 5 stars$14.88-0.2%$15.33+3.1%+14.8%$7.39B$4.44B20.109,000Analyst UpgradeAnalyst RevisionRGCRegencell Bioscience0.2513 of 5 stars$14.68-0.5%N/AN/A$7.29BN/A0.0010Gap DownLEGNLegend Biotech3.579 of 5 stars$39.44+1.2%$72.70+84.3%-28.6%$7.25B$627.24M-66.852,609News CoverageAnalyst ForecastAnalyst RevisionRVMDRevolution Medicines4.5461 of 5 stars$38.37+0.9%$68.00+77.2%-16.8%$7.15B$11.58M-9.59250Analyst ForecastGRFSGrifols3.5357 of 5 stars$9.72-0.2%$10.30+6.0%+22.4%$6.68B$7.81B8.3123,822News CoverageTGTXTG Therapeutics3.6841 of 5 stars$38.92+4.9%$43.80+12.5%+78.6%$6.18B$329M162.17290Positive News Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Elanco Animal Health Alternatives Regencell Bioscience Alternatives Legend Biotech Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts